PlainPharmaWatch

CMS Open Payments · Tool

Evoke Pharma, Inc. vs Nexxt Spine LLC

Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.

A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.

Compare Different Companies

vs

Relationship comparison

Which recorded payment profile is more concentrated?

Nexxt Spine LLC has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 576, versus 422 for the other company. Its single largest recorded recipient represents 0.1% of that company's General Payments recipient total.

HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.

Evoke Pharma, Inc.
HHI 422 · top recipient 0.1%
Ranked #1,358 of 1,838 companies by HHI
Nexxt Spine LLC
HHI 576 · top recipient 0.1%
Ranked #1,245 of 1,838 companies by HHI

Payment Overview

Company A

Evoke Pharma, Inc.

Total Payments
$292.8K
% of Industry
0.0%
Transactions
3,417
Avg per Transaction
$85.68
Recipients
3,417
Avg per Recipient
$85.68
Payment Types
5
Top Payment Type
Compensation for Services Other Than Consulting
Company B

Nexxt Spine LLC

Total Payments
$292.8K
% of Industry
0.0%
Transactions
358
Avg per Transaction
$817.96
Recipients
358
Avg per Recipient
$817.96
Payment Types
6
Top Payment Type
Royalty or License

Highlighted values indicate the higher figure for each metric.

Total payments compared

Evoke Pharma, Inc. vs Nexxt Spine LLC - total reported payments in CMS Open Payments PY2024

Nexxt Spine LLC$292.8KEvoke Pharma, Inc.$292.8K

Payment Types Breakdown

Evoke Pharma, Inc.

Compensation for Services Other Than Consulting $168.5K

57.5%

Food and Beverage $84.0K

28.7%

Travel and Lodging $36.4K

12.4%

Honoraria $2.5K

0.9%

Consulting Fee $1.4K

0.5%

Nexxt Spine LLC

Royalty or License $185.7K

63.4%

Consulting Fee $45.3K

15.5%

Travel and Lodging $26.1K

8.9%

Food and Beverage $19.0K

6.5%

Compensation for Services Other Than Consulting $15.8K

5.4%

Entertainment $826.62

0.3%

Top 5 General-Payment Recipients

This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.

Evoke Pharma, Inc.

  1. 1

    JIGNESH SHAH

    $31,000.42 · 32 txns

  2. 2

    SUSAN TRACY WOLGAMOTT

    $24,096.81 · 31 txns

  3. 3

    DAKSESH BIPIN PATEL

    $19,083.79 · 25 txns

  4. 4

    ABDELHAI ABDELQADER

    $16,866.81 · 14 txns

  5. 5

    FRED FOWLER

    $16,840.00 · 20 txns

Nexxt Spine LLC

  1. 1

    Alexander C Lemons

    $33,292.21 · 7 txns

  2. 2

    John W Klekamp

    $29,697.37 · 3 txns

  3. 3

    Theodore Belanger

    $28,970.00 · 1 txns

  4. 4

    Michael J McNamara

    $23,005.16 · 2 txns

  5. 5

    Kamran Parsa

    $19,739.06 · 11 txns

Summary Comparison

Metric Evoke Pharma, Inc. Nexxt Spine LLC
Total Payments $292.8K $292.8K
% of Industry Total 0.0% 0.0%
Transaction Count 3,417 358
Avg per Transaction $85.68 $817.96
Recipient Count 3,417 358
Avg per Recipient $85.68 $817.96
Payment Type Count 5 6
Top Payment Type Compensation for Services Other Than Consulting Royalty or License

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.